|
| 34862243 | Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. | Clin Cancer Res | 2022 |
| 34921024 | Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. | Clin Cancer Res | 2022 |
| 34140638 | Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. | Br J Cancer | 2021 |
| 33824280 | CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo. | Oncogenesis | 2021 |
| 33903593 | PAX8 and MECOM are interaction partners driving ovarian cancer. | Nat Commun | 2021 |
| 33563973 | p53 dynamics vary between tissues and are linked with radiation sensitivity. | Nat Commun | 2021 |
| 33615182 | Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms. | ACS Pharmacol Transl Sci | 2021 |
| 33554304 | Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201. | AAPS J | 2021 |
| 32099592 | Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models. | Comput Struct Biotechnol J | 2020 |
| 30598450 | Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. | Proc Natl Acad Sci U S A | 2019 |
| 30217415 | In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. | Bioorg Med Chem Lett | 2018 |
| 30135191 | Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. | Cancer Res | 2018 |
| 29092942 | PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. | Cancer Res | 2017 |
| 28265066 | Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf<sup>-/-</sup> mouse model. | Proc Natl Acad Sci U S A | 2017 |
| 27659046 | High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. | Cancer Res | 2016 |
| 27852439 | Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | Elife | 2016 |
| 25965177 | A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | Elife | 2015 |
| 26479923 | High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Nat Med | 2015 |
| 26181851 | Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. | J Med Chem | 2015 |
| 24321855 | First full-beam PET acquisitions in proton therapy with a modular dual-head dedicated system. | Phys Med Biol | 2014 |
| 24786664 | Proton range monitoring with in-beam PET: Monte Carlo activity predictions and comparison with cyclotron data. | Phys Med | 2014 |
| 24608574 | Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. | Mol Cancer Ther | 2014 |
| 24528602 | Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice. | BMC Cancer | 2014 |
| 23267074 | M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. | Proc Natl Acad Sci U S A | 2013 |
| 20008843 | Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability. | Clin Cancer Res | 2010 |
| 19462209 | Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. | Mol Imaging Biol | 2009 |
| 19724681 | Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. | Neoplasia | 2009 |
| 18811057 | Minimally invasive biomarkers for therapy monitoring. | Ernst Schering Found Symp Proc | 2007 |
| 16339780 | Effect of adenosine A2A receptor activation in murine models of respiratory disorders. | Am J Physiol Lung Cell Mol Physiol | 2006 |
| 15723258 | Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. | Cancer Chemother Pharmacol | 2005 |
| 16278399 | Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. | Clin Cancer Res | 2005 |
| 15918178 | PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. | NMR Biomed | 2005 |
| 12819855 | Differential DNA synthesis in response to activation of protease-activated receptors on cultured guinea-pig tracheal smooth muscle cells. | Naunyn Schmiedebergs Arch Pharmacol | 2003 |
| 12574382 | IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. | J Immunol | 2003 |